Form 4: Director Andrew Gengos Receives Stock Option Grant
Statement of Changes in Beneficial Ownership
Turn Therapeutics Inc. director Andrew Gengos was granted 95,000 stock options with an exercise price of $5.75.
Summary
- Director Andrew Gengos received a grant of 95,000 stock options on June 4, 2026.
- The options have an exercise price of $5.75 per share.
- The options vest in twelve equal monthly installments starting June 30, 2026, contingent on continued service.
- The grant was issued under the company's 2025 Omnibus Incentive Plan.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation that carries no significant signal regarding company performance.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
Negatives
- The grant results in potential future dilution for existing shareholders.
Risks
- Vesting is subject to continued service, which could be impacted by unforeseen changes in board composition.
Future Outlook
The options vest over a one-year period, indicating a short-term retention and incentive structure for the director.
Industry Context
StockSavvy.ai notes that equity grants to directors are standard corporate governance practice to ensure alignment with shareholder interests, particularly in the biotechnology sector where long-term development cycles are common.
Comparison to Industry Standards
- The use of a 12-month vesting schedule for director options is relatively aggressive compared to the typical 3-4 year vesting schedules seen in broader industry standards.
- The exercise price aligns with standard practice of setting strike prices at or near the market value at the time of grant.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Compensation | Grant of 95,000 options under the 2025 Omnibus Incentive Plan. | 06/04/2026 | Standard alignment of director incentives. |
Stakeholder Impact
- Minor dilution impact on existing shareholders upon potential future exercise of options.
Next Steps
- Vesting of the first installment of options on June 30, 2026.
Key Dates
| Date | Description |
|---|---|
| 06/04/2026 | Date of option grant transaction |
| 06/08/2026 | Date of filing |
| 06/30/2026 | Commencement of vesting period |
| 06/04/2036 | Expiration date of options |
Keywords
Turn Therapeutics, TTRX, Form 4, Insider Trading, Stock Options, Equity Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.